This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): bepotastine besilate intranasal solution
Description: Bepotastine besilate is a non-sedating, highly selective antagonist of the histamine H1 receptor. It has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment for nasal symptoms associated with allergic rhinitis.
A fixed dose combination of bepotastine and a steroid is also being developed.
Deal Structure: In September 2007, we obtained exclusive North American rights to nasal dosage forms of bepotastine, an investigational product for the treatment of allergy symptoms, from Mitsubishi Tanabe.
Bausch + Lomb and ISTA
In March 2012, Bausch + Lomb and ISTA Pharmaceuticals announced that they have signed a definitive agreement under which Bausch + Lomb will acquire ISTA. This acquisition closed in June 2012.
Bausch + Lomb and Valeant
In May 2013, Valeant and Bausch + Lomb announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.
In August 2013, Valeant announced it has completed the previously announced acquisition of Bausch + Lomb.
Partners: Mitsubishi Tanabe Pharma Corporation
Pink Sheet Weekly Trademark Review May 22, 2012
Additional information available to subscribers only: